Back to Market Feed

Product Information

SKYRIZI 360 MG/2.4 ML ON-BODY is a brand product labeled by AbbVie Inc., priced at $9565.6005 per ML under NDC 00074107001. Its NADAC has been published 105 times since Aug 21, 2024.

SKYRIZI 360 MG/2.4 ML ON-BODY

Risankizumab-rzaa
$9565.6005per ML

Manufacturer

AbbVie Inc.

NDC

00074107001

Classification

Brand

Dosage Form

KIT

Route

INTRAVENOUS

Effective Date

8/19/2026

Approval Type

Biologic (BLA)

FDA Application

BLA761105

On Market Since

6/16/2022

Price Statistics

The NADAC for SKYRIZI 360 MG/2.4 ML ON-BODY has been published 105 times since Aug 21, 2024, and over the history we have for it it has risen 12.3%. The table below summarizes its recorded NADAC range and movement.

Current price$9565.6005 per ML
All-time high$9679.4921 (Jul 15, 2026)
All-time low$8515.5350 (Aug 21, 2024)
52-week high$9679.4921
52-week low$9069.0448
Median price$9069.0448
Average price$9143.9026
Largest weekly change+6.5% (Jan 8, 2025)
Weeks tracked105
Tracking sinceAug 21, 2024

Price History

1W

+0.3%

1M

-1.2%

3M

-1.2%

6M

-1.2%

1Y

+5.5%

3Y

N/A

5Y

N/A

All

+12.3%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Risankizumab-rzaa market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

No related drugs found.

Frequently asked questions

What is the NADAC price of SKYRIZI 360 MG/2.4 ML ON-BODY?

The current National Average Drug Acquisition Cost (NADAC) for SKYRIZI 360 MG/2.4 ML ON-BODY, manufactured by AbbVie Inc., is $9565.6005 per ML (NDC 00074107001), effective Aug 19, 2026.

How has the price of SKYRIZI 360 MG/2.4 ML ON-BODY changed over time?

Over the history we have for it, the NADAC for SKYRIZI 360 MG/2.4 ML ON-BODY has risen 12.3%. It has been tracked across 105 weekly CMS publications since Aug 21, 2024.

What are the highest and lowest recorded NADAC prices for SKYRIZI 360 MG/2.4 ML ON-BODY?

Since Aug 21, 2024, the NADAC for SKYRIZI 360 MG/2.4 ML ON-BODY has ranged from a low of $8515.5350 (Aug 21, 2024) to a high of $9679.4921 (Jul 15, 2026), with a median of $9069.0448 per ML.

Are there cheaper alternatives to SKYRIZI 360 MG/2.4 ML ON-BODY?

No other NADAC-published product currently shares the active ingredient and strength of SKYRIZI 360 MG/2.4 ML ON-BODY in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures SKYRIZI 360 MG/2.4 ML ON-BODY?

SKYRIZI 360 MG/2.4 ML ON-BODY (NDC 00074107001) is labeled by AbbVie Inc., and CMS classifies it as a brand product.